XCL2 and cancer: The results showed significant XCL2 expression in various immune subtypes in 13 out of 16 cancers, including ACC (six subtypes), BRCA (five subtypes), CESC (three subtypes), HNSC (five subtypes), KIRC (six subtypes), KIRP (six subtypes), LUAD (five subtypes), SARC (five subtypes), SKCM (five subtypes), STAD (five subtypes), THCA (five subtypes), UCEC (five subtypes), and UVM (three subtypes) (Supplementary Figure 3A–3M).